The Molecular Cytogenetics Core provides valuable scientific and technical support to MSK investigators exploring the role of chromosomal instability in cancer. This is accomplished through appropriate and efficient experiment design, custom multi-color DNA-FISH probe design and development, data analysis and interpretation, and support with manuscript/grant preparation. Currently, the Core provides 2 main categories of specialized service that operate at the single-cell level on a variety of human and animal model research samples: conventional karyotyping and fluorescence in situ hybridization (FISH). Conventional karyotyping is routinely performed to confirm cell line identity, screen targeted mouse ESC clones intended for blastocyst injection, monitor the stability of cultured stem cells over time, and measure chromosomal instability/heterogeneity as an experimental endpoint. Over the years, the Core has assembled a broad range of molecular cytogenetics resources (plasmids, BAC clones, individual whole chromosome painting probes), allowing the Core to provide FISH services at significantly lower cost. FISH-based assays are routinely employed to map genes or transgene integration sites, detect aneuploidy/chromosomal instability, co-detect DNA/protein and assess intra-tumoral heterogeneity; tests include custom probe development, locus-specific FISH, whole-chromosome painting (WCP), spectral karyotyping (SKY), Q-FISH, and Immuno-FISH. The Core is equipped with 5 modern Fluorescence imaging systems including 2 with a wide range of applications that can be fully or partially automated. The Core also provides training in tissue culture, karyotyping, and FISH. During the past grant period, the services and collaborative work provided by the Molecular Cytogenetics Core have supported the research of 84 investigators from 8 research program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084813
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Jakub, James W; Peled, Anne Warren; Gray, Richard J et al. (2018) Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg 153:123-129
Ulaner, Gary A; Lyashchenko, Serge K; Riedl, Christopher et al. (2018) First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. J Nucl Med 59:900-906
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
McFarland, Daniel C; Shaffer, Kelly M; Tiersten, Amy et al. (2018) Physical Symptom Burden and Its Association With Distress, Anxiety, and Depression in Breast Cancer. Psychosomatics 59:464-471
Aherne, Emily A; Plodkowski, Andrew J; Montecalvo, Joseph et al. (2018) What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? Lung Cancer 118:83-89
Perrin, Thomas; Midya, Abhishek; Yamashita, Rikiya et al. (2018) Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. Abdom Radiol (NY) 43:3271-3278
Apte, Aditya P; Iyer, Aditi; Crispin-Ortuzar, Mireia et al. (2018) Technical Note: Extension of CERR for computational radiomics: A comprehensive MATLAB platform for reproducible radiomics research. Med Phys :
Santini, Fernando C; Rizvi, Hira; Plodkowski, Andrew J et al. (2018) Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res 6:1093-1099
Ma, Jennifer; Setton, Jeremy; Lee, Nancy Y et al. (2018) The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun 9:3292

Showing the most recent 10 out of 8799 publications